Glucosamine Unum In Die [Once A Day] Efficacy (GUIDE) Trial: Glucosamine Sulfate in Patients With Knee Osteoarthritis
This study has been completed.
Sponsor:
Rottapharm
Information provided by:
Rottapharm
ClinicalTrials.gov Identifier:
NCT00110474
First received: May 9, 2005
Last updated: September 18, 2006
Last verified: September 2006
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary objective of this study is to evaluate the efficacy and safety of glucosamine sulfate versus placebo on the symptoms of knee osteoarthritis after 6 months of treatment, using acetaminophen as a reference symptomatic medication.
| Condition | Intervention | Phase |
|---|---|---|
|
Knee Osteoarthritis |
Drug: Glucosamine sulfate Drug: Acetaminophen |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | Efficacy and Safety of Glucosamine Sulfate Versus a Pure Analgesic (Acetaminophen/Paracetamol) and Placebo in Patients Suffering From Osteoarthritis of the Knee |
Resource links provided by NLM:
MedlinePlus related topics:
Osteoarthritis
Drug Information available for:
Glucosamine hydrochloride
Acetaminophen
Glucosamine
Sulfate ion
Glucosamine sulfate
U.S. FDA Resources
Further study details as provided by Rottapharm:
Primary Outcome Measures:
- Lequesne Index
Secondary Outcome Measures:
- WOMAC Index
- OARSI Responder Criteria
| Estimated Enrollment: | 300 |
| Study Start Date: | May 2000 |
| Estimated Study Completion Date: | December 2002 |
Show Detailed Description
Eligibility| Ages Eligible for Study: | 45 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Diagnosis of knee osteoarthritis according to the clinical and radiological criteria of the American College of Rheumatology (ACR), with minimum symptom severity/characteristics
Exclusion Criteria:
- Standard exclusions apply
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00110474
Locations
| Portugal | |
| Hospital Universitario de Coimbra | |
| Coimbra, Portugal | |
| Hospital Egaz Moniz | |
| Lisboa, Portugal | |
| Hospital Conde do Bertiandos | |
| Ponte de Lima, Portugal | |
| Spain | |
| Complejo Hospitalario Juan Canalejo | |
| A Coruña, Spain | |
| Hospital del Mar | |
| Barcelona, Spain | |
| Hospital Clinic | |
| Barcelona, Spain | |
| Completo Hospitalario de Ciudad Real | |
| Ciudad Real, Spain | |
| Hospital Universitario La Paz | |
| Madrid, Spain | |
| Fundacíón Jiménez Díaz | |
| Madrid, Spain | |
| Hospital de La Pricesa | |
| Madrid, Spain | |
| Hospital Donostia | |
| San Sebastian, Spain | |
| Hospital Nuestra Señora de Valme | |
| Sevilla, Spain | |
| Hospital Dr. Peset | |
| Valencia, Spain | |
Sponsors and Collaborators
Rottapharm
Investigators
| Study Director: | Gabriel Herrero-Beaumont, MD | Fundacíón Jiménez Díaz - Madrid - Spain |
More Information
Publications:
Herrero-Beaumont G, Román JA, Trabado MC, Blanco FJ, Benito P, Martin-Mola E, et al. Effects of glucosamine sulfate on 6-month control of knee osteoarthritis symptoms vs. placebo and acetaminophen: results from the Glucosamine Unum In Die Efficacy (GUIDE) trial [abstract]. Arthritis Rheum 2005;9 Suppl: 1203.
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00110474 History of Changes |
| Other Study ID Numbers: | JN151198 |
| Study First Received: | May 9, 2005 |
| Last Updated: | September 18, 2006 |
| Health Authority: | Spain: Spanish Agency of Medicines |
Keywords provided by Rottapharm:
|
Glucosamine sulfate Osteoarthritis Acetaminophen Paracetamol Clinical trial |
Additional relevant MeSH terms:
|
Osteoarthritis Osteoarthritis, Knee Arthritis Joint Diseases Musculoskeletal Diseases Rheumatic Diseases Acetaminophen Antipyretics |
Physiological Effects of Drugs Pharmacologic Actions Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 16, 2013